Anavex Life Sciences Corp.
AVXLNasdaqCIK 1314052HealthcareFiscal year ends Sep 30
Reports and events: 223 filings
Newest first, by EDGAR acceptance time (Eastern). Each filing’s page lists its documents on sec.gov and, for 10-K and 10-Q reports, the extracted sections.
What the forms are: 10-K, 10-Q, 8-K, Form 4, DEF 14A, Schedule 13D, Schedule 13G, amendments, accession numbers.
| Filed | Form | What it is | Accession number |
|---|---|---|---|
| 2026-10-2020:16 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-001351 |
| 2026-10-1520:18 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-001348 |
| 2026-09-2821:27 ET | 8-K | 5.01 Change in control; 5.07 Shareholder vote results | 0001731122-26-001294 |
| 2026-09-0921:17 ET | 8-K | 8.01 Other events | 0001731122-26-001211 |
| 2026-09-0221:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-001179 |
| 2026-08-2820:28 ET | 10-Q | Quarterly reportPeriod 2026-06-30 | 0001731122-26-001167 |
| 2026-08-2820:26 ET | 10-Q | Quarterly reportPeriod 2026-03-31 | 0001731122-26-001166 |
| 2026-08-2820:25 ET | 10-Q/A | Quarterly report, amendedPeriod 2025-12-31 | 0001731122-26-001165 |
| 2026-08-2820:24 ET | 10-K/A | Annual report, amendedPeriod 2025-09-30 | 0001731122-26-001164 |
| 2026-08-2512:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001731122-26-001143 |
| 2026-08-1712:10 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001731122-26-001078 |
| 2026-08-1121:00 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001731122-26-001042 |
| 2026-08-0312:26 ET | 8-K | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001731122-26-001000 |
| 2026-07-3012:15 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001731122-26-000988 |
| 2026-07-2012:59 ET | 8-K | 8.01 Other events | 0001731122-26-000957 |
| 2026-06-2610:15 ET | 8-K | 8.01 Other events | 0001731122-26-000889 |
| 2026-05-2212:15 ET | 8-K | 3.01 Delisting notice; 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-000781 |
| 2026-05-1520:15 ET | 8-K | 5.02 Departure or appointment of officers or directors | 0001731122-26-000744 |
| 2026-05-0611:04 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001731122-26-000678 |
| 2026-03-2520:06 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-26-000482 |
| 2026-02-2511:07 ET | 8-K | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001731122-26-000305 |
| 2026-02-0921:40 ET | 10-Q | Quarterly reportPeriod 2025-12-31 | 0001731122-26-000200 |
| 2026-02-0912:31 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001731122-26-000193 |
| 2025-11-2521:31 ET | 10-K | Annual reportPeriod 2025-09-30 | 0001731122-25-001596 |
| 2025-11-2512:30 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001731122-25-001591 |
| 2025-11-1412:42 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-25-001536 |
| 2025-08-1220:08 ET | 10-Q | Quarterly reportPeriod 2025-06-30 | 0001731122-25-001105 |
| 2025-07-2823:26 ET | 8-K | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001731122-25-001033 |
| 2025-07-0321:25 ET | 8-K | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001731122-25-000935 |
| 2025-06-1321:30 ET | 8-K | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001731122-25-000878 |
| 2025-05-1320:31 ET | 10-Q | Quarterly reportPeriod 2025-03-31 | 0001731122-25-000724 |
| 2025-04-2520:31 ET | DEF 14A | Proxy statementPeriod 2025-04-25 | 0001731122-25-000607 |
| 2025-02-1214:06 ET | 10-Q | Quarterly reportPeriod 2024-12-31 | 0001731122-25-000205 |
| 2024-12-2321:30 ET | 10-K | Annual reportPeriod 2024-09-30 | 0001731122-24-002041 |
| 2024-08-0621:21 ET | 10-Q | Quarterly reportPeriod 2024-06-30 | 0001731122-24-001207 |
| 2024-07-3021:20 ET | 8-K | 1.02 Termination of a material agreement | 0001731122-24-001160 |
| 2024-06-2120:30 ET | 8-K | 5.07 Shareholder vote results | 0001731122-24-001003 |
| 2024-05-0920:35 ET | 10-Q | Quarterly reportPeriod 2024-03-31 | 0001731122-24-000760 |
| 2024-05-0912:00 ET | 8-K | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001731122-24-000758 |
| 2024-05-0610:01 ET | DEF 14A | Proxy statementPeriod 2024-05-06 | 0001731122-24-000730 |
| 2024-02-0721:31 ET | 10-Q | Quarterly reportPeriod 2023-12-31 | 0001731122-24-000206 |
| 2023-11-2721:30 ET | 10-K | Annual reportPeriod 2023-09-30 | 0001731122-23-002197 |
| 2023-08-0820:30 ET | 10-Q | Quarterly reportPeriod 2023-06-30 | 0001731122-23-001412 |
| 2023-05-2420:30 ET | 8-K | 5.07 Shareholder vote results | 0001731122-23-001007 |
| 2023-05-0920:31 ET | 10-Q | Quarterly reportPeriod 2023-03-31 | 0001731122-23-000845 |
| 2023-04-1410:01 ET | 8-K | 5.03 Amendment to articles or bylaws; 9.01 Financial statements and exhibits | 0001731122-23-000651 |
| 2023-04-0420:33 ET | DEF 14A | Proxy statementPeriod 2023-04-04 | 0001731122-23-000573 |
| 2023-03-1323:32 ET | 8-K | 7.01 Regulation FD disclosure | 0001731122-23-000348 |
| 2023-02-0722:20 ET | 8-K | 8.01 Other events; 9.01 Financial statements and exhibits | 0001731122-23-000156 |
| 2023-02-0722:11 ET | 10-Q | Quarterly reportPeriod 2022-12-31 | 0001731122-23-000152 |
Source: SEC EDGAR, the company’s filing index. Last ingested by Listed: Oct 24, 2026, 15:11 ET. Listed shows no prices and gives no investment advice.